CRH Medical Announces Significant Acquisition

Transaction marks significant expansion of CRH's gastrointestinal business

VANCOUVER, Dec. 2, 2014  - CRH Medical Corporation (TSX:CRH.TO ) (OTCQX:CRMMF ) ("CRH" or the "Company"), a North American medical company focused on providing physicians with innovative products and services for the treatment of gastrointestinal diseases, today announced the acquisition (the "Transaction") of the business, assets and interests of Gastroenterology Anesthesia Associates, LLC, ("GAA"). GAA is one of the largest providers of anesthesiology services to gastroenterologists in the southeastern United States.

The Company will pay US$58.6 million at closing with up to an additional US$14.6 million payable within 4.5 years based on agreed financial performance requirements of the acquired business. The maximum total purchase price assuming achievement of all performance measures is US$73.2 million.

Lakeland Industries Provides Update on Business Activity Relating to Ebola Crisis

RONKONKOMA, N.Y., Oct. 29, 2014 -- Lakeland Industries, Inc. (NASDAQ:LAKE - News), a leading global manufacturer of industrial protective clothing for industry, municipalities, healthcare and to first responders on the federal, state and local levels, today provided the following update on recent business activities and corporate developments.

In anticipation of the worsening of the Ebola crisis, on September 12 the Company announced its intent to increase manufacturing capacity for specialty protective suits to be worn by healthcare workers and others being exposed to Ebola.

Amedisys Reports Third Quarter Financial Results

BATON ROUGE, La., Oct. 29, 2014 -- Amedisys, Inc. (AMED), a leading home health and hospice company, today reported its financial results for the three and nine-month periods ended September 30, 2014.

Three-Month Periods Ended September 30, 2014 and 2013

• After adding back for the 2014 period, $1.0 million ($0.6 million, net of income tax) or $0.02 per diluted share and for the 2013 period $145.0 million ($90.2 million, net of income tax) or $2.86 per diluted share for certain items*, our adjusted results from continuing operations were as follows:
  • Net service revenue of $300.3 million compared to $301.3 million in 2013.

    Published: 29 October 2014

    Written by Editor

    Financial Results   Up on News  

    Read more: Amedisys Inc ( AMED )

NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling

Combines NGS and FISH Testing for Comprehensive Cancer Profiling

FT. MYERS, Fla., Oct.  16, 2014 -- NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, announced today the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing ("NGS") to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization ("FISH") methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci.